Concepedia

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

Inken Salewski, Julia Henne, Leonie Engster, Paula Krone, Björn Schneider, Caterina Redwanz, Heiko Lemcke, Larissa Henze, Claudia Maletzki

OncoImmunology · 2022 · 22 citations · 38 references

DOIFull text

Open access

Concepts

Abstract

. The immune-modulatory potential of abemaciclib renders this compound ideal for dMMR patients not eligible for ICI treatment.

References

38

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

, , +16

CDK4/6 inhibition triggers anti-tumour immunity

Shom Goel, Molly J. DeCristo, April C. Watt et al. · Nature · 2017 · 1.5K citations · Full text

, , +12

IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses

Thomas Krausgruber, Katrina Blazek, Tim Smallie et al. · Nature Immunology · 2011 · 1.3K citations · Full text

, , +14

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

Steven J. Lemery, Patricia Keegan, Richard Pazdur · New England Journal of Medicine · 2017 · 658 citations

, , +17

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text

, , +17